Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2006-01-31
2006-01-31
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C560S009000, C560S015000
Reexamination Certificate
active
06992105
ABSTRACT:
Compounds of the formulawherein R, R1, COOR2, R3–R7, alk, and X have meaning as defined, such being useful as dual inhibitors of angiotensin converting enzyme and neutral endopeptidase, as well as inhibitors of endothelin converting enzyme.
REFERENCES:
patent: 5214181 (1993-05-01), Morita et al.
patent: 5506244 (1996-04-01), Fink
patent: 5508266 (1996-04-01), Fink
patent: 5591891 (1997-01-01), Fournie-Zaluski et al.
patent: 5801274 (1998-09-01), Fournie-Zaluski et al.
patent: 5994293 (1999-11-01), Baxter et al.
patent: 6162828 (2000-12-01), Fukuda et al.
patent: 6284914 (2001-09-01), Fujisawa et al.
patent: 6492421 (2002-12-01), Thorsett et al.
patent: 6495522 (2002-12-01), Wang et al.
patent: 6503949 (2003-01-01), Lau et al.
patent: 6552079 (2003-04-01), Scarborough et al.
patent: 6576766 (2003-06-01), Weigele et al.
patent: 6635621 (2003-10-01), Singh et al.
patent: 6670393 (2003-12-01), Schwartz et al.
patent: 6803383 (2004-10-01), Boger et al.
patent: 2002/0004500 (2002-01-01), Reeves et al.
patent: 2002/0013307 (2002-01-01), Lapuerta et al.
patent: WO 93/02099 (1993-02-01), None
patent: WO 99/19346 (1999-04-01), None
patent: WO 99/24461 (1999-05-01), None
patent: WO 99/55723 (1999-11-01), None
patent: WO 99/55726 (1999-11-01), None
patent: WO 00/40600 (2000-07-01), None
patent: WO 00/43414 (2000-07-01), None
Robl J.A. et al., “Recent Advances in the Design and Development of Vasopeptidase Inhibitors”, Expert Opinion on therapeutic Patents, Ashley Publications, GB, vol. 9, No. 12, pp. 1665-1667 (1999).
Coric et al., “Optimal Recongnition of Neutral Endopeptidase and Angiotensin-Converting Enzyme Active Sites by Mercaptoacyldipeptides as a means to Design Potent Dual Inhibitors”, J. Med. Chem., vol. 39, No. 6, pp. 1210-1219 (1996).
Bhagwat et al., “alpha-Mercaptoacyl Dipeptides that inhibit Angiotensin converting Enzyme and neutral Endopeptidase 24. 11”, Bioorganic & Medicinal Chemistry letters, vol. 5, No. 7, pp 735-738 (1995).
Bell et al., “The Synthesis, NMR Spectroscopy, and X-ray Structure of a new Rhenium N2S2Chelate Complex”, Inorg. Chem. vol. 37, No. 14, pp. 3517-3520 (1998).
Lambkin Deborah C.
Novartis
Novartis AG
LandOfFree
Dipeptide derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dipeptide derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dipeptide derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3561509